- Cladribine - mechanism of action2017 | First Faculty of Medicine
- Treatment of multiple sclerosis with oral cladribine: results of clinical trials2017 | First Faculty of Medicine
- Cladribine versus fingolimod, natalizumab and interferon for multiple sclerosis2018 | First Faculty of Medicine
- Long-term management of oral cladribine treatment in multiple sclerosis2021 | Faculty of Medicine in Hradec Králové, First Faculty of Medicine, Faculty of Medicine in Pilsen
- Oral cladribine and multiple sclerosis - efficacy and safety data update2019 | Faculty of Medicine in Pilsen
- Oral cladribine in the treatment of multiple sclerosis - data from the national registry ReMuS(R) registry2021 | Faculty of Medicine in Hradec Králové, First Faculty of Medicine, Second Faculty of Medicine, Faculty of Medicine in Pilsen
- Treatment of Multifocal Multisystem BRAF Positive Langerhans Cell Histiocytosis with Cladribine, Surgery and Allogenic Stem Cell Transplantation2017 | Faculty of Medicine in Hradec Králové
- Treatment satisfaction, safety, and tolerability of cladribine tablets in patients with highly active relapsing multiple sclerosis: CLARIFY-MS study 6-month interim analysis2022 | Faculty of Medicine in Hradec Králové, First Faculty of Medicine
- Treatment satisfaction, safety, and tolerability of cladribine tablets in patients with highly active relapsing multiple sclerosis : CLARIFY-MS study 6-month interim analysis2022 | Faculty of Medicine in Hradec Králové, First Faculty of Medicine
- Perorální terapie RS- výsledky klinických studií s cladribinemPublication without faculty affiliation
- A plain language summary on the effectiveness of cladribine tablets compared with other oral treatments for multiple sclerosis: results from the MSBase registry2023 | First Faculty of Medicine
- Improvements in quality of life over 2 years with cladribine tablets in people with relapsing multiple sclerosis: The CLARIFY-MS study2023 | First Faculty of Medicine
- Expert opinion on the long-term use of cladribine tablets for multiple sclerosis: Systematic literature review of real-world evidence2023 | First Faculty of Medicine
- Comparing switch to ocrelizumab, cladribine or natalizumab after fingolimod treatment cessation in multiple sclerosis2022 | First Faculty of Medicine
- Comparative effectiveness of cladribine tablets versus other oral disease-modifying treatments for multiple sclerosis: Results from MSBase registry2023 | First Faculty of Medicine
- Fludarabine vs cladribine plus busulfan and low-dose TBI as reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation : a prospective randomized trial2007 | First Faculty of Medicine
- Fludarabine vs cladribine plus busulfan and low-dose TBI as reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation : a prospective randomized trial2007 | Faculty of Physical Education and Sport
- Hematopoietic Stem Cell Transplantation From Haploidentical Donors in Aplasia After Cladribine/Cytarabine Chemotherapy for Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome2019 | First Faculty of Medicine
- Does the development of new drugs for multiple sclerosis change the prognosis of the patient ?2011 | First Faculty of Medicine
- Does the development of new drugs for multiple sclerosis change the prognosis of the patient?2011 | First Faculty of Medicine
- Pulmonary damage in a patient with hairy cell leukemia - infectious involvement or hematological disease activity? Case report2023 | Faculty of Medicine in Hradec Králové, Faculty of Pharmacy in Hradec Králové
- Lymphoma-like course in aggressive adult multisystem Langerhans cell histiocytosis and the benefit of PET/CT imaging in evaluation of diffuse metabolic activity of lung parenchyma2010 | Second Faculty of Medicine
- Chemotherapy, radiotherapy and surgery in chronic lymphocytic leukemia treatment2010 | Third Faculty of Medicine
- Downregulation of deoxycytidine kinase in cytarabine-resistant mantle cell lymphoma cells confers cross-resistance to nucleoside analogs gemcitabine, fludarabine and cladribine, but not to other classes of anti-lymphoma agents2014 | First Faculty of Medicine
- Additional treatment with 2-Chloro-2-Deoxyadenosine during consolidation in children with high-risk acute myeloid leukemia does not improve survival2015 | Second Faculty of Medicine
- Detailed Functional and Proteomic Characterization of Fludarabine Resistance in Mantle Cell Lymphoma Cells2015 | First Faculty of Medicine
- The significance of clofarabine in the therapy of adult patient with acute myeloid leukemia2012 | Faculty of Medicine in Hradec Králové
- Clinical case: idelalisib-induced immunoglobulin flare2017 | Third Faculty of Medicine, Central Library of Charles University
- Bone Marrow Fibrosis During the Therapy of Hairy Cell Leukemia2004 | First Faculty of Medicine
- Immunosuppressive drugs in treating neurological diseases2011 | Publication without faculty affiliation